ARCA Biopharma Inc (ABIO) Stock
ABIO is no longer traded. ARCA Biopharma was delisted from the Nasdaq in August 2024.
Prices on this page are historical; the last trade was August 30, 2024 at $2.40.
ARCA Biopharma stock price history
ABIO final trading statistics
- Final close
- $2.40
- Final trading day
- Aug 30, 2024
- Market cap at delisting
- $34.82M
- Shares outstanding
- 1.21M
- Final 52-week range
- $1.56 – $4.49
- Avg. volume (final 3 mo.)
- 63,104
- All-time high (split-adj.)
- $1000000.00 · Aug 1997
- All-time low (split-adj.)
- $2.40 · Aug 2024
- Return since IPO
- -100.0%
- Beta
- 0.90
- Book value / share
- $2.25
- Price / book
- 1.07
ARCA Biopharma annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2023 | $0.00 | -$5.3M | -$0.37 |
| FY2022 | $0.00 | -$9.3M | -$1.01 |
| FY2021 | $0.00 | -$19.2M | -$1.55 |
| FY2020 | $0.00 | -$9.7M | -$2.44 |
| FY2019 | $0.00 | -$5.5M | -$4.53 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About ARCA Biopharma Inc
ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
ARCA Biopharma stock FAQ
What happened to ARCA Biopharma stock?
ARCA Biopharma stock was delisted from the Nasdaq. Its final close was $2.40 on August 30, 2024.
Is ABIO stock still trading?
No. ABIO was delisted from the Nasdaq in August 2024 and no longer trades on a U.S. exchange.
What was the last price of ABIO stock?
ABIO closed at $2.40 on its final trading day, August 30, 2024, for a market value of about $34.82M.
What were ARCA Biopharma's revenue and earnings in its last full fiscal year?
ARCA Biopharma reported revenue of $0.00 and net income of -$5.3M in fiscal 2023, its last full year as a public company.
When did ARCA Biopharma go public?
ARCA Biopharma Inc stock began trading on August 8, 1997.